#Sweden #Stockholm #EpiFinder #GenomePro #Epigenica AB

Introduction to EpiFinder™ GenomePro

Epigenica AB, a frontrunner in epigenomic innovation, recently announced the release of its groundbreaking EpiFinder™ GenomePro. This state-of-the-art platform is set to transform the landscape of epigenomic research, enabling scientists to decode intricate post-translational histone modifications (hPTMs) and DNA methylation with remarkable throughput and cost-efficiency, all while ensuring exceptional data quality.

Features of EpiFinder™ GenomePro

The EpiFinder™ GenomePro represents a next-generation advancement over its predecessor, EpiFinder™ Genome. It offers optimized reagents and more efficient protocols, allowing the analysis of up to 24 samples in a single run. Researchers can obtain robust quantitative data across 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles pertaining to various hPTMs and DNA methylation from minimal sample quantities. The reduced cost per sample significantly lowers barriers for conducting large-scale studies.

One key aspect of the EpiFinder™ GenomePro is its flexible design. Researchers can select desired hPTMs with or without the inclusion of DNA methylation, making it adaptable to a wide range of investigative focuses. Furthermore, the open-source data analysis pipeline facilitates unparalleled transparency and reproducibility in findings, a crucial factor for scientific advancements.

Enhancing Epigenomic Research

Mohamad Takwa, CEO of Epigenica AB, stated, "With the introduction of EpiFinder™ GenomePro, we are establishing a new standard in epigenomic research. Our vision is to provide a platform that not only delivers valuable insights but also empowers researchers to tackle complex biological questions on an unprecedented scale."

The implications of EpiFinder™ GenomePro reach far into various therapeutic areas, aiding in the decoding of epigenetic mechanisms linked to the onset and progression of diseases, while also predicting patient responses to treatments. By providing high-resolution, comprehensive epigenomic data, EpiFinder™ GenomePro equips researchers to discover new biomarkers, map complex disease processes, and derive insights that facilitate the development of targeted and precise therapies.

Value for Laboratories

The versatility of this platform enables exploration across the entire spectrum of epigenetic regulation, translating insights into actionable strategies for understanding and treating diseases. Björn Reinius, an associate professor at the Karolinska Institute, praised the EpiFinder™ GenomePro kit, suggesting it is an invaluable method for laboratories with limited experience in ChIP-seq or similar methodologies, enabling them to generate high-quality ChIP-seq data efficiently and without a significant time investment.

The protocol is designed for minimal optimization, allowing users to produce quantitative ChIP-seq libraries and conduct initial data analysis without extensive effort.

Commitment to Cost-Effective Research Solutions

Epigenica AB is dedicated to equipping researchers with tools to generate cost-effective, high-throughput, multiplex, and quantifiable data for comprehensive epigenomic insights. To learn more about how EpiFinder™ GenomePro can revolutionize your research, visit Epigenica AB’s official website at www.epigenica.se.

About Epigenica

Epigenica is a biotechnological firm at the forefront of epigenetic research innovations. The company’s EpiFinder platform allows researchers to conduct extensive epigenetic studies with unprecedented speed, scalability, and affordability. Epigenica is constructing a product portfolio based on the EpiFinder platform, offering extensive high-throughput profiling with varying depths of detail and a wide array of potential starting materials. Founded in Stockholm, Sweden in 2020, Epigenica is financed through venture capital.